Holen Sie sich die Stockscreener-App
47.53
4.03%
1.84
Handel nachbörslich:
47.75
0.22
+0.46%
Anaptysbio Inc Aktie (ANAB) Neueste Nachrichten
AnaptysBio (NASDAQ:ANAB) Sets New 1-Year HighWhat's Next? - MarketBeat
AnaptysBio (NASDAQ:ANAB) CFO Sells $705,266.25 in Stock - MarketBeat
Eric Loumeau Sells 10,000 Shares of AnaptysBio (NASDAQ:ANAB) Stock - MarketBeat
AnaptysBio (NASDAQ:ANAB) Insider Eric Loumeau Sells 12,500 Shares - MarketBeat
Avoiding Lag: Real-Time Signals in (ANAB) Movement - news.stocktradersdaily.com
AnaptysBio stock hits 52-week high at 47.95 USD - Investing.com
AnaptysBio stock hits 52-week high at 47.95 USD By Investing.com - Investing.com UK
Squarepoint Ops LLC Invests $2.43 Million in AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio (ANAB) Price Target Lowered by Barclays, Maintains Ov - GuruFocus
Vanda submits BLA to FDA for generalized pustular psoriasis drug By Investing.com - Investing.com Nigeria
Vanda Announces Submission of Biologics License Application to the FDA for Imsidolimab for the Treatment of Generalized Pustular Psoriasis - marketscreener.com
Vanda (Nasdaq: VNDA) seeks priority FDA review of BLA for GPP drug imsidolimab - Stock Titan
JP Morgan maintains a sell rating on GSK plc (GSK) - MSN
683 Capital Management LLC Has $11.10 Million Stock Holdings in AnaptysBio, Inc. $ANAB - MarketBeat
Camber Capital Management LP Sells 625,000 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
AnaptysBio stock hits 52-week high at 46.57 USD - Investing.com
AnaptysBio stock hits 52-week high at 46.57 USD By Investing.com - Investing.com Canada
Stifel Nicolaus Lowers AnaptysBio (NASDAQ:ANAB) Price Target to $56.00 - MarketBeat
AnaptysBio (ANAB) Analyst Rating Update: Stifel Lowers Price Tar - GuruFocus
Beyond the Gluten-Free Diet: A New Era in Celiac Disease Treatment - BioSpace
J&J sends AnaptysBio lower with mid-stage trial data for anti-inflammatory agent - MSN
J.P. Morgan Maintains a Sell Rating on GSK plc (GSK) - Finviz
AnaptysBio (NASDAQ:ANAB) Hits New 1-Year HighStill a Buy? - MarketBeat
Discipline and Rules-Based Execution in ANAB Response - news.stocktradersdaily.com
33,369 Shares in AnaptysBio, Inc. $ANAB Acquired by Panagora Asset Management Inc. - MarketBeat
AnaptysBio Files Legal Complaint Against GSK and Tesaro - MSN
AnaptysBio (ANAB): Assessing Valuation After Legal Battle Over Jemperli Royalties and Future Cash Flows Escalates - Sahm
AnaptysBio (NASDAQ:ANAB) Reaches New 1-Year HighHere's Why - MarketBeat
30,642 Shares in AnaptysBio, Inc. $ANAB Bought by XTX Topco Ltd - MarketBeat
Geode Capital Management LLC Sells 27,809 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Will AnaptysBio Inc. stock deliver consistent dividendsWeekly Stock Report & Daily Volume Surge Trade Alerts - Newser
AnaptysBio Stock Gets A Price Target Hike After Announcing Plan To Separate Royalty, Biopharma Businesses – Check Out The New Level - MSN
AnaptysBio stock hits 52-week high at 43.35 USD - Investing.com
AnaptysBio stock hits 52-week high at 43.35 USD By Investing.com - Investing.com Nigeria
AnaptysBio Shares Navigate Legal Headwinds Amid Strong Performance - AD HOC NEWS
How institutional buying supports AnaptysBio Inc. stockMarket Performance Recap & Smart Money Movement Alerts - Newser
Why AnaptysBio Inc. (AN6) stock could break out in 2025Market Activity Recap & Real-Time Market Trend Scan - Newser
The Bull Case For AnaptysBio (ANAB) Could Change Following Jemperli Legal Clash With GSK Subsidiary - Yahoo Finance
Virtus Investment Advisers LLC Sells 6,909 Shares of AnaptysBio, Inc. $ANAB - MarketBeat
Jemperli Royalty Dispute Could Be a Game Changer for AnaptysBio (ANAB) - Sahm
Is AnaptysBio Inc. (AN6) stock a top hedge fund pickQuarterly Growth Report & Real-Time Market Sentiment Reports - Newser
What sentiment indicators say about AnaptysBio Inc. stockPortfolio Return Report & Entry and Exit Point Strategies - Newser
ANAB: AnaptyBio Among Top Quality Stocks with High Returns - GuruFocus
AnaptysBio, GSK's Tesaro Unit Likely Settle Jemperli Dispute Before July, Wedbush Says - marketscreener.com
A Look at AnaptysBio's Valuation as Litigation With GSK Over Jemperli Royalties Draws Investor Focus - simplywall.st
AnaptysBio Reports Q3 2025 Results and Strategic Plans - MSN
Why AnaptysBio Inc. stock could rally in 2025Portfolio Update Report & AI Powered Buy and Sell Recommendations - BỘ NỘI VỤ
AnaptysBio FY2025 EPS Estimate Boosted by HC Wainwright - MarketBeat
AnaptysBio, Inc. (NASDAQ:ANAB) Given Average Recommendation of "Moderate Buy" by Analysts - MarketBeat
AnaptysBio's complaint against Tesaro for breaching agreement was publicly filed on Nov 26SEC filing - marketscreener.com
AnaptysBio files lawsuit against Tesaro and GSK over license deal - StreetInsider
AnaptysBio, Inc Files Lawsuit Against Tesaro and GSK - TradingView
0.31%
0.33%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):